• Lead Drug FGL Found To Prevent Impaired Cognition
• R&D Update, Publication & Conference Presentation
• CHDI selects ENKAM’s compounds for preclinical tes
• Presentation at BIO-Europe
• Attendance at Conferences
• Participation at Conference
• The ENKAM approach shows potential in treatment of
• Discovery of Novel Compound Classes
• Positive Preclinical Data - Traumatic Brain Injury
• Appointment of Executive Chairman
• New Promising Treatment of Alzheimer’s Disease
• EU 6FP Grants EUR9.7 million to European Research
• Glossary

PARTICIPATION AT CONFERENCE

IN CNS THERAPEUTICS AND ALZHEIMER’S DISEASE SESSION

________________________________________________________________

Copenhagen, September 26 2006 - ENKAM Pharmaceuticals A/S, the privately owned, Copenhagen-based biotechnology company focused on cancer and neurodegenerative diseases, is pleased to announce that it will participate in the Biotech Forum + Scanlab conference in Copenhagen which runs from 26^th to 28^th September 2006.

Enkam will present information alongside Wyeth and Eli Lilly in the CNS Therapeutics and Alzheimer’s disease session on Wednesday 26^th September. At the conference Professor Vladimir Berezin, one of Enkam’s founders from the University of Copenhagen, whose work the company was pioneered upon, will present information on the “Neuroprotective and Cognition-enhancing Properties of Novel NCAM-derived FGF-receptor Agonists: Implication for Treatment of Alzheimer’s Disease”.

Commenting on this announcement, Morten Albrechtsen MD, Chief Executive and a founder of ENKAM Pharmaceuticals, said:“We are delighted to be participating in this important conference particularly alongside such prestigious industry companies as Wyeth and Eli Lilly.”

Ends